Latest Insider Transactions at Arvinas, Inc. (ARVN)
This section provides a real-time view of insider transactions for Arvinas, Inc. (ARVN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ARVINAS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ARVINAS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 18
2025
|
Noah Berkowitz Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,658
-7.3%
|
$69,264
$8.59 P/Share
|
|
Feb 24
2025
|
Angela M Cacace Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,207
-2.09%
|
$67,312
$16.65 P/Share
|
|
Feb 24
2025
|
David K Loomis Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,214
-6.05%
|
$19,424
$16.75 P/Share
|
|
Feb 24
2025
|
John G Houston President and CEO |
SELL
Open market or private sale
|
Direct |
31,338
-1.32%
|
$501,408
$16.65 P/Share
|
|
Feb 24
2025
|
Ian Taylor President, R&D |
SELL
Open market or private sale
|
Direct |
9,020
-2.7%
|
$144,320
$16.65 P/Share
|
|
Feb 13
2025
|
Andrew Saik Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
49,092
+30.76%
|
-
|
|
Feb 13
2025
|
David K Loomis Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,584
+36.24%
|
-
|
|
Feb 13
2025
|
Angela M Cacace Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
49,092
+32.72%
|
-
|
|
Feb 13
2025
|
Noah Berkowitz Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
55,229
+31.76%
|
-
|
|
Feb 13
2025
|
Ian Taylor President, R&D |
BUY
Grant, award, or other acquisition
|
Direct |
20,619
+10.92%
|
-
|
|
Feb 13
2025
|
John G Houston President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
152,000
+11.34%
|
-
|
|
Nov 07
2024
|
David K Loomis Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
231
-2.79%
|
$6,237
$27.69 P/Share
|
|
Jun 24
2024
|
Andrew Saik Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
61,409
+50.0%
|
-
|
|
Jun 17
2024
|
Angela M Cacace Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,995
+23.58%
|
-
|
|
May 29
2024
|
Linda Bain Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,899
+37.06%
|
-
|
|
May 29
2024
|
Alsup Laurie Smaldone Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,899
+37.06%
|
-
|
|
May 29
2024
|
Leslie V Norwalk Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,899
+37.06%
|
-
|
|
May 29
2024
|
John D Young Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,899
+37.06%
|
-
|
|
May 29
2024
|
Briggs Morrison Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,899
+16.43%
|
-
|
|
May 29
2024
|
Sunil Agarwal Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,899
+29.44%
|
-
|
|
May 29
2024
|
Edward Moore Kennedy Jr. Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,899
+20.13%
|
-
|
|
May 29
2024
|
Everett Cunningham Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,899
+37.06%
|
-
|
|
May 21
2024
|
Randy Teel Int. Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,300
+18.31%
|
-
|
|
Mar 18
2024
|
Noah Berkowitz Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
63,452
+50.0%
|
-
|
|
Feb 23
2024
|
Sean A Cassidy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,702
-0.93%
|
$79,994
$47.05 P/Share
|
|
Feb 23
2024
|
John G Houston President and CEO |
SELL
Open market or private sale
|
Direct |
5,196
-0.5%
|
$244,212
$47.05 P/Share
|
|
Feb 23
2024
|
John G Houston President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
124,450
+10.67%
|
-
|
|
Feb 23
2024
|
David K Loomis Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,750
+40.35%
|
-
|
|
Feb 23
2024
|
Ian Taylor President, R&D |
SELL
Open market or private sale
|
Direct |
1,701
-1.14%
|
$79,947
$47.05 P/Share
|
|
Feb 23
2024
|
Ian Taylor President, R&D |
BUY
Grant, award, or other acquisition
|
Direct |
39,250
+20.83%
|
-
|
|
Feb 23
2024
|
Ronald Peck Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,699
-2.45%
|
$79,853
$47.05 P/Share
|
|
Feb 23
2024
|
Ronald Peck Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
39,250
+36.19%
|
-
|
|
Jan 04
2024
|
Ian Taylor President, R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
8,252
+6.98%
|
$132,032
$16.0 P/Share
|
|
Nov 08
2023
|
David K Loomis Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
229
-2.69%
|
$3,893
$17.05 P/Share
|
|
Aug 11
2023
|
Ronald Peck Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,324
-4.23%
|
$31,776
$24.39 P/Share
|
|
Aug 11
2023
|
Ronald Peck Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,010
+11.36%
|
-
|
|
Jun 15
2023
|
Sunil Agarwal Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,242
+50.0%
|
-
|
|
Jun 15
2023
|
Linda Bain Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,121
+50.0%
|
-
|
|
Jun 15
2023
|
Everett Cunningham Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,121
+50.0%
|
-
|
|
Jun 15
2023
|
Wendy L Dixon Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,121
+31.12%
|
-
|
|
Jun 15
2023
|
Edward Moore Kennedy Jr. Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,121
+19.05%
|
-
|
|
Jun 15
2023
|
Briggs Morrison Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,121
+14.6%
|
-
|
|
Jun 15
2023
|
Leslie V Norwalk Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,121
+50.0%
|
-
|
|
Jun 15
2023
|
Alsup Laurie Smaldone Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,121
+50.0%
|
-
|
|
Jun 15
2023
|
John D Young Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,121
+50.0%
|
-
|
|
Mar 01
2023
|
John G Houston President and CEO |
SELL
Open market or private sale
|
Direct |
5,878
-0.64%
|
$170,462
$29.53 P/Share
|
|
Mar 01
2023
|
John G Houston President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,510
+1.86%
|
-
|
|
Mar 01
2023
|
Ian Taylor President, R&D |
SELL
Open market or private sale
|
Direct |
1,051
-1.02%
|
$30,479
$29.53 P/Share
|
|
Mar 01
2023
|
Ian Taylor President, R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
2,685
+2.55%
|
-
|
|
Mar 01
2023
|
Sean A Cassidy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,745
-0.94%
|
$50,605
$29.53 P/Share
|